Chronic Kidney Disease. Dr. Rachel Carson Nephrologist With thanks to Dr. Gaylene Hargrove and Dr. Nancy Craven
|
|
- Esmond Warner
- 7 years ago
- Views:
Transcription
1 Chronic Kidney Disease Dr. Rachel Carson Nephrologist With thanks to Dr. Gaylene Hargrove and Dr. Nancy Craven
2 Disclosures Speaker fees from Sanofi and Bristol- Myers-Squibb for community CME
3 Mr. Hales Current Age: 57 BP 140/85 Smoking: quit Weight: 203 lbs BMI: 29.1 A1C 6.7 egfr 53, ACR 38
4 What intervention is most effective in delaying the progression to ESRD? A. Dietary protein restriction (0.6 g/kg/d) B. Optimal BP control (<130/80) C. ACEI/ARB therapy D. Optimal glycemic control E. Weight reduction F. Smoking cessation
5 Which of the following statements is true of Mr. Hales? A. He has established diabetic nephropathy, so he will need dialysis/transplant in the future, despite optimal intervention. B. His current blood pressure (140/85) is acceptable. C. It is possible to normalize the ACR and stabilize egfr with optimal, multi-faceted intervention. D. He should be referred to a nephrologist urgently.
6 Mr. Hales is likely to experience a CV event before he requires renal replacement therapy. A. TRUE B. FALSE
7 The Challenge In Canada 22% of Canadians years of age have hypertension 50% of Canadians >65 years of age have hypertension Hypertensive patients who are treated but BP uncontrolled Hypertensive patients who are treated and BP controlled 21% 13% 9% 22% 43% Diabetic patients Who are treated and BP controlled Patients who are aware but remain untreated and BP uncontrolled Hypertensive patients who are unaware Joffres et al. Am J Hyper 2001
8 Prevalence of Hypertension in Type 2 Diabetes Normoalbuminuria (n = 323) Microalbuminuria (n = 151) Macroalbuminuria (n = 75) Total (n = 549) % Prevalence of hypertension (BP 140/90 mm Hg) 50 0 Tarnow L et al. Diabetes Care 1994
9 Diabetic Nephropathy and Albuminuria Diabetic nephropathy is the #1 cause of ESRD in Canada & Western World Normal range MAU Macroalbuminuria mg/day µg/min Albumin excretion rate (AER) Maher JF Am Fam Physician 1992 Meltzer et al. CMAJ 1998 ESRD=End Stage Renal Disease
10 Proteinuria Predicts Stroke and CHD Events in Type 2 Diabetes A: U-Prot <150 mg/l B: U-Prot mg/l C: U-Prot >300 mg/l Survival curves for CV mortality Overall: p<0.001 A B C Incidence (%) p< Stroke CHD events Miettinen H et al. Stroke 1996 Months U-Prot = Urinary protein concentration
11 Relative Importance of Microalbuminuria in Prediction of Mortality Odds ratio Microalbuminuria Smoking Diastolic BP Cholesterol Eastman RC et al. Lancet 1997
12 ONCE NEPHROPATHY IS PRESENT, PTS ARE MORE LIKELY TO DIE THAN TO PROGRESS Consider annual risk for 100 pts at each stage of DN No nephropathy D Microalbuminuria Macroalbuminuria Plasma Cr >175 or RRT 5097 patients in UKPDS: Adler et al Kidney Int 2003;63: E A T H
13 Preserving Renal Function Blood Pressure Control/RAS Blockade Best evidence to support target of <130/80 is UKPDS data (each 10 mmhg reduces risk by 12%) IRMA-2 2 trial (Irbesartan( Irbesartan) 70% RR in progression from MAU to overt nephropathy; normalization of ACR possible IDNT trial (Irbesartan( Irbesartan) Decreased risk of CV death, CHF, doubling of SCr,, and ESRD in DM2 pts with macroalbuminuria RENAAL trial (Losartan( Losartan) Similar composite endpoint reduction in DM2 pts with well-established established CKD (egfr < 60 ml/min)
14 BP REDUCTION IS WHERE THE MONEY IS UKPDS data, Bakris et al AJKD 2000
15 Bakris et al, AJKD 2000
16 IRMA 2: Primary Endpoint Development of Overt Proteinuria RRR=70% p<0.001 RRR=39% p=0.08 Subjects (%) Usual care (n=201) 150 mg (n=195) 300 mg (n=194) Parving H-H et al. N Engl J Med 2001 Irbesartan
17 IRMA 2: Normalization of Urinary Albumin Excretion Rate p= Subjects (%) Usual care (n=201) 150 mg (n=195) 300 mg (n=194) Parving H-H et al. N Engl J Med 2001 Irbesartan
18 RENAAL Trial: Post-Hoc Analyses Most significant risk factor for progressive CKD was severity of proteinuria Every 10 mmhg increase in SBP increased risk of ESRD or death by 6.7% 18% decrease in risk of CV event for every 50% decrease in rate of albumin excretion For all levels of achieved BP, larger reduction in albuminuria correlated with lower risk of ESRD
19 Preserving Renal Function Primary Prevention of Nephropathy ADVANCE trial (Perindopril( Perindopril+ Indapamide) 11,000 DM2 pts fewer developed new onset MAU compared to controls, 19.6% vs 23.6%) BENEDICT trial (Trandolopril( Trandolopril) 1204 DM2 pts significant reduction in new onset MAU in treated vs controls (30 vs 18 events)
20 Preserving Renal Function Conclusions from ACEI/ARB Trials Blockade of the RAS is renoprotective in pts with DM2 and hypertension (prevents onset of incipient nephropathy) ACEI/ARB Tx stabilizes and can even improve renal fn in pts with established nephropathy The renoprotective effects of RAS blockade are independent of BP control ( Control Group in trials had equivalent BP control)
21 Preserving Renal Function Dietary Protein Restriction 2 small trials in Diabetes (NEJM 1991, Lancet 1989) 0.6 g/kg/d vs usual protein intake slowed rate of decline in GFR by 60-75% ie.. From 12 ml/min/yr to 3 ml/min/yr MDRD (NEJM 1994) 585 moderate CKD pts (lots of Polycystic Kidneys) 0.6 g/kg/d vs 1.3 g/kg/d showed small benefit only after 4 mos 255 severe CKD pts 0.3 g/kg/d vs 0.6 g/kg/d showed marginally slower decline Potential problems: Compliance Increased risk of protein malnutrition normal protein intake is 1.5 g/kg/day Moderate reduction is 1 g/kg/day (recommended)
22 Preserving Renal Function STENO 2 Trial Combined Therapy 160 pts randomized to standard vs intensive multifactorial Tx Diet, exercise, smoking cessation ACEI Tx (independent of BP) ASA Tx in pts with CAD, PVD BP goal < 140/85 HbA1c < 6.5% Tchol < 5.0; TG<1.65
23 Preserving Renal Function STENO 2 Trial Combined Therapy Mean F/U 7.8 yrs Primary end point progression to overt nephropathy at 4 yrs; composite CV endpoint at 8 yrs Significant improvement in albuminuria (-20 vs +30 mg/d) Reduced progression to overt nephropathy (20% vs 39%)
24 What about the very elderly? Beckett et al (NEJM 2008) RCT of 3,845 pts from Europe, China, Australasia aged >80 yrs with SBP>160, creat < 150 Well (<15% with DM, cardiovascular dz) Indapamide +/- Perindopril vs placebo Target BP <150/80 2 year follow up 21% reduction in all-cause mortality 64% reduction in heart failure
25 CAUTION: CAUSES OF FALSE POSITIVE Urine ACR Fever Exercise CHF (decompensated( decompensated) Poor glycemic control Urinary tract infection Hematuria
26 Preserving Renal Function Summary/Recommendations Parameters to monitor Q3monthly: BP (home BP monitoring useful) SCr/eGFR Urine ACR HbA1c Lipids Q6-12 monthly Therapeutic Goals: BP < 130/80; ACEI/ARB first line Tx Normalize urine ACR; use ACEI/ARB even if normotensive Slow decline in egfr LDL chol < 2.0 mmol/l if CAD
27 Preserving Renal Function Summary/Recommendations Algorithm for treating HTN: ACEI or ARB first line Tx Titrate to maximum dose tolerated Repeat SCr,, K within 1 week Add diuretic (loop diuretic if GFR < 35 ml/min) If BP target not reached, add CCB, or beta-blocker blocker If persistent albuminuria combined ACEI/ARB Tx?
28 ACEi plus ARB? YES! CALM (2000) 199 DM HTN pts w MAU, candesartan and lisinopril Lower BP, mild additional reduction of albuminuria CHARM-added (2003) 2548 CHF pts candesartan plus ACEi fewer CV death or CHF hospitalizations COOPERATE (2003) 263 Japanese non-dm pts, losartan trandalapril Slowed renal progression and reduced proteinuria Kunz Meta-analysis analysis (Ann Int Med Jan 2008) greater reduction in proteinuria (18-25%) but no renal outcome data NO! ONTARGET (NEJM April 2008) 6365 pts w DM Ramipril telmisartan no outcome benefit, greater risk of renal impairment and adverse effects VALIANT (2003) 14,703 pts w MI and CHF valsartan and captopril no outcome benefit, increased adverse reactions MAYBE! ValHeFT (2001) 5010 pts w CHF, valsartan + ACEi less CHF, better QOL, BUT if pt already on BBL and ACEi,, higher mortality
29 ACEi / ARB Therapy: SAFE USE / MONITORING Check serum K and creatinine at initiation of therapy or at time of dose change and wks later Start with low doses ACE/ARB medications should be held in the event of significant systemic illness (fever, vomiting, diarrhea) to avoid a pre-renal renal insult If K 5 5.5, Potassium-restricted diet (Renal Dietician now available in Nanaimo!) consider reducing dose if possible, d/c drugs that interfere with K excretion: NSAIDs, Septra,, potassium salts, potassium-sparing sparing diuretics Prescribe thiazide or loop diuretics If none of these work, THEN discontinue ACEi/ARB
30 Additional Anti-hypertensive options Look for dual indications Alpha blockers prostatic disease (Terazosin, Prazosin, Doxazosin) Sympatholytics anxiety (Clonidine 0.1 mg BID, caution with discontinuation) Direct Vasodilators - male pattern hair loss (Minoxidil, Hydralazine)
31 Hidden Factors Salt NSAIDS Etoh Over the counter drugs (decongestants) Tricyclics,, MAO inhibitors Anabolic steroids Oral contraceptives Caffeine (energy drinks) Illegal drugs (cocaine, methamphetamine) Secondary Hypertension? Renal Artery Stenosis (fibromuscular dysplasia or atherosclerotic) Hyperaldosteronism (hypokalemia) Hypercortisolism Pheochromocytoma Coarctation of the aorta (BP in both arms +/- legs) Obstructive sleep apnea
32 Preserving Renal Function Lifestyle Modification Dietary Sodium restriction 100 mmol/d = 2300 mg/d Consider doing 24h urine collection for Na to assess dietary compliance Weight Loss (can reduce (can reduce albuminuria,, BP, improve glycemic control) Smoking Cessation Regular Exercise Dietary Protein restriction (1.0 Moderation of ETOH (re: BP control) (1.0 g/kg/d)
33 What intervention is most effective in delaying the progression to ESRD? A. Dietary protein restriction (0.6 g/kg/d) B. Optimal BP control (<130/80) C. ACEI/ARB therapy D. Optimal glycemic control E. Weight reduction F. Smoking cessation
34 Which of the following statements is true of Mr. Hales? A. He has established diabetic nephropathy, so he will need dialysis/transplant in the future, despite optimal intervention. B. His current blood pressure (140/85) is acceptable. C. It is possible to normalize the ACR and stabilize egfr with optimal, multi-faceted intervention. D. He should be referred to a nephrologist urgently.
35 Mr. Hales is likely to experience a CV event before he requires renal replacement therapy. A. TRUE B. FALSE
36 What to tell Mr. Hales? Commend him re: Smoking cessation Good glycemic control (A1c 6.7%) Parameters to treat: BP ACEI/ARB; goal BP < 130/80 Albuminuria ACEI/ARB Weight aim for BMI <= 25 Lipids; goal LDL < 2.0
37 GRAND OPENING! Early Bird Special! The VIHA Kidney Care Clinic is moving into the Beaufort Centre (old NRGH Foundation office) Opening Day November 3rd RN Renal Dietician Social Worker Early Education for patients with egfr >50 Learning Session #1 (pts with egfr 30-60) Learning Session #2 (pts with egfr <30)
38 Thank you! Questions Welcome
39 Reaching Target: Combination Therapy TPR x CO = MAP TPR Reduction ACEi ARB CCB Direct Renin Inhibitors (Aliskiren/Rasilez) Alpha Blockers Other Vasodilators (Hydralazine, Minoxidil) HR/Contractility Reduction BBL CCB Centrally Acting agents (Clonidine) Preload Reduction Thiazide Diuretics Loop Diuretics Potassium Sparing Diuretics Venodilators (NTG) Centrally Acting Agents (Clonidine)
40 Assessing Alcohol Intake Frequency During the past 12 months, how often, on average, did you drink alcoholic beverages? Everyday 4-66 times/week 2-33 times/week Once per week 1-33 times per month Less than once per month Abstainer/not applicable Quantity On the days when you drank alcohol, how many drinks did you usually have? Rehm J, Int J Epidemiol 1999;28:
Diabetic Nephropathy
Diabetic Nephropathy Kidney disease is common in people affected by diabetes mellitus Definition Urinary albumin excretion of more than 300mg in a 24 hour collection or macroalbuminuria Abnormal renal
More informationDiabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.
Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years
More informationUsing multiple biomarkers to predict renal and cardiovascular drug efficacy: Implications for drug development and registration
Using multiple biomarkers to predict renal and cardiovascular drug efficacy: Implications for drug development and registration Hiddo Lambers Heerspink Department of Clinical Pharmacology University Medical
More informationUnderstanding diabetes Do the recent trials help?
Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.
More informationHYPERTENSION ASSOCIATED WITH RENAL DISEASES
RENAL DISEASE v Patients with renal insufficiency should be encouraged to reduce dietary salt and protein intake. v Target blood pressure is less than 135-130/85 mmhg. If patients have urinary protein
More informationHypertension and Diabetes
Hypertension and Diabetes C.W. Spellman, D.O., Ph.D., FACOI Professor & Associate Dean Research Dir. Center Diabetes & Metabolic Disorders Texas Tech University Health Science Center Midland-Odessa, Texas
More informationRenal Disease in Type 2 Diabetes Mellitus
Renal Disease in Type 2 Diabetes Mellitus 6th Collaborative DiGP/HSE/UCC Conference 25 th September 2013 Dr. Eoin O Sullivan Consultant Endocrinologist Bon Secours Hospital Cork Case 69 year old woman
More informationPROCEEDINGS DIABETIC NEPHROPATHY: DETECTION AND TREATMENT OF RENAL DISEASE IN PATIENTS WITH DIABETES* Jiten Vora, MA, MD, FRCP ABSTRACT
DIABETIC NEPHROPATHY: DETECTION AND TREATMENT OF RENAL DISEASE IN PATIENTS WITH DIABETES* Jiten Vora, MA, MD, FRCP ABSTRACT Diabetic nephropathy affects people with either type 1 or type 2 diabetes mellitus.
More informationPrevention and management of chronic kidney disease in type 2 diabetes
162..194 NEPHROLOGY 2010; 15, S162 S194 doi:10.1111/j.1440-1797.2010.01240.x Prevention and management of chronic kidney disease in type 2 diabetes Date written: April 2009nep_1240 Final submission: April
More informationManagement of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8)
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) Adapted by Capital Health Plan Approved by Quality Improvement
More informationChronic Kidney Disease (CKD) Algorithm. Chronic Kidney Disease (CKD) Algorithm Page 1
Chronic Kidney Disease (CKD) Algorithm Chronic Kidney Disease (CKD) Algorithm Page 1 Chronic Kidney Disease (CKD) Algorithm (See NICE Clinical Guideline CG73 1 and Quality Standards 2 ) Who should have
More informationPrediction of Kidney Disease Progression in Patients with Diabetes
Prediction of Kidney Disease Progression in Patients with Diabetes John Arthur, MD, PhD Medical University of South Carolina SEKDC Meeting September 8, 2012 Objectives Understand the importance of predicting
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More informationADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More informationDiabetes and the Kidneys
Diabetes and the Kidneys Aim(s) and objective(s) This guideline focuses on the detection, prevention, and management of kidney disease in people with diabetes. The management of end-stage renal disease
More informationIn many diabetes units, people with type
Renal Microalbuminuria: Screening and management in type 2 diabetes Julia Arundale Introduction In many diabetes units, patients with type 1 or type 2 diabetes are screened for proteinuria. Screening for
More informationGuideline for Microalbuminuria Screening
East Lancashire Diabetes Network Guideline for Microalbuminuria Screening Produced by: Task and Finish Group, Clinical Standards Group Produced: August 2006 Approved by: East Lancashire Diabetes Network
More informationMicroalbuminuria: We are in the midst of an epidemic: the epidemic. So What s a Little Protein? Malcolm s diabetes. How much is too much?
Focus on CME at the University of Saskatchewan Microalbuminuria: So What s a Little Protein? By Judith T. Klassen, BSc, MD, FRCPC University of Saskatchewan Practical Management of Common Medical Problems
More informationMetabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007
Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering
More informationDefinition, Prevalence, Pathophysiology and Complications of CKD. JM Krzesinski CHU Liège-ULg Core curriculum Nephrology September 28 th 2013
Definition, Prevalence, Pathophysiology and Complications of CKD JM Krzesinski CHU Liège-ULg Core curriculum Nephrology September 28 th 2013 KI supplements January 2013 Objectives of the course on CKD:
More informationHypertension Guidelines
Overview Hypertension Guidelines Aim to reduce Blood Pressure to 140/90 or less (140/80 for diabetics), adding drugs as needed until further treatment is inappropriate or declined. N.B. patients do not
More informationAlbuminuria versus GFR as markers of diabetic CKD progression
Albuminuria versus GFR as markers of diabetic CKD progression KDIGO Controversies Conference: Diabetic Kidney Disease New Delhi, March 2012 Richard J MacIsaac PhD FRACP Director of Endocrinology & Diabetes,
More informationRenovascular Hypertension
Renovascular Hypertension Philip Stockwell, MD Assistant Professor of Medicine (Clinical) Warren Alpert School of Medicine Cardiology for the Primary Care Provider September 28, 201 Renovascular Hypertension
More informationADULT HYPERTENSION PROTOCOL STANFORD COORDINATED CARE
I. PURPOSE To establish guidelines for the monitoring of antihypertensive therapy in adult patients and to define the roles and responsibilities of the collaborating clinical pharmacist and pharmacy resident.
More informationVascular Risk Reduction: Addressing Vascular Risk
Vascular Risk Reduction: Addressing Vascular Risk Vascular Risk Reduction (VRR) Welcome! Presentation & Activities Focus: Managing known risk factors for vascular disease. Engage, collaborate and have
More informationJNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates. January 30, 2014
JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates January 30, 2014 GOALS Review key recommendations from recently published guidelines on blood pressure and cholesterol management Discuss
More informationDrug Treatment in Type 2 Diabetes with Hypertension
Hypertension is 1.5 2 times more prevalent in Type 2 diabetes (prevalence up to 80 % in diabetic subjects). This exacerbates the risk of cardiovascular disease by ~ two-fold. Drug therapy reduces the risk
More informationAggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost
Aggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost Naftali Stern Institute of Endocrinology, Metabolism and Hypertension Tel Aviv -Sourasky Medical Center and Sackler
More informationChronic Kidney Disease and the Electronic Health Record. Duaine Murphree, MD Sarah M. Thelen, MD
Chronic Kidney Disease and the Electronic Health Record Duaine Murphree, MD Sarah M. Thelen, MD Definition of Chronic Kidney Disease (CKD) Defined by the National Kidney Foundation Either a decline in
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationGUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY*
71 GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY* Ryuichi KIKKAWA** Asian Med. J. 44(2): 71 75, 2001 Abstract: Diabetic nephropathy is the most devastating complication of diabetes and is now the
More informationAntihypertensive Drug Management to Achieve Systolic Blood Pressure <120 mmhg in SPRINT
Antihypertensive Drug Management to Achieve Systolic Blood Pressure
More informationCardiovascular Risk in Diabetes
Cardiovascular Risk in Diabetes Lipids Hypercholesterolaemia is an important reversible risk factor for cardiovascular disease and should be tackled aggressively in all diabetic patients. In Type 1 patients,
More informationTreatment of Hypertension: JNC 8 and More
PL Detail-Document #300201 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER February 2014 Treatment of
More informationHypertension Guideline V4
Hypertension Guideline V4 Approved 24/06/2008 Version VERSION 4 FINAL Date of First Issue 26/02/08 Review Date 01/03/2010 Date of Issue 24/06/2008 EQIA Yes / No 24/06/2008 Author / Contact Dr Leslie Cruickshank
More informationKDIGO CLINICAL PRACTICE GUIDELINE FOR LIPID MANAGEMENT IN CHRONIC KIDNEY DISEASE. Supplemental Tables November 2013
KDIGO CLINICAL PRACTICE GUIDELINE FOR LIPID MANAGEMENT IN CHRONIC KIDNEY DISEASE Supplemental Tables November 2013 Suppl Table 1: Summary table of RCT examining the effect of exercise in CKD 5HD patients
More informationDRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE DRUGS IN DIABETIC PATIENTS WITH CKD
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Elhami et al. SJIF Impact Factor 5.210 Volume 4, Issue 11, 1159-1166 Research Article ISSN 2278 4357 DRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE
More informationSpecial Communication
Clinical Review & Education Special Communication 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National
More informationType of outcome measures: The search strategy MEDLINE (OVID)
Types of participants: Inclusion criteria: Randomized controlled trials, examining effect of Renin-angiotensin system blockade on the renal and cardiovascular events in patients with chronic kidney disease
More informationSecondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence
Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for
More informationHypertension and Heart Failure Medications. Dr William Dooley
Hypertension and Heart Failure Medications Dr William Dooley Plan Heart Failure Acute vs. chronic Mx Hypertension Common drugs used Method of action Choice of medications Heart Failure Aims; Short term:
More informationHYPERTENSION: Comparison of New Guidelines
HYPERTENSION: Comparison of New Guidelines L. Brian Cross, PharmD, BCACP, CDE Vice-Chair & Associate Professor Bill Gatton College of Pharmacy Department of Pharmacy Practice Associate Professor James
More informationGuidelines for the management of hypertension in patients with diabetes mellitus
Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes
More informationEasy or complex? University Pharmacy. Pharm.D. candidates, 2011
High Blood Pressure Easy or complex? University Pharmacy Edwin Elliot, Insia Hussain Pharm.D. candidates, 2011 The evolution of mankind 2.5 mn years 50 years and we wonder why our healthcare costs are
More informationGFR (Glomerular Filtration Rate) A Key to Understanding How Well Your Kidneys Are Working
GFR (Glomerular Filtration Rate) A Key to Understanding How Well Your Kidneys Are Working www.kidney.org National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Did you know that the National
More informationCase Study 6: Management of Hypertension
Case Study 6: Management of Hypertension 2000 Scenario Mr Ellis is a fit 61-year-old, semi-retired market gardener. He is a moderate (10/day) smoker with minimal alcohol intake and there are no other cardiovascular
More informationCombination Antihypertensive Therapy: When to use it Diabetes
Combination Antihypertensive Therapy: When to use it Diabetes George L. Bakris, MD, F.A.S.N., F.A.S.H. Professor of Medicine Director, ASH Comprehensive Hypertension Center The University of Chicago Medicine
More informationGuidance for Industry Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims
Guidance for Industry Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
More informationHigh Blood Pressure and Chronic Kidney Disease. For People With CKD Stages 1 4
High Blood Pressure and Chronic Kidney Disease For People With CKD Stages 1 4 National Kidney Foundation s Kidney Disease Outcomes Quality Initiative (NKF-KDOQI ) The National Kidney Foundation s Kidney
More informationHigh Blood Pressure and Kidney Disease
High Blood Pressure and Kidney Disease National Kidney and Urologic Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH The kidneys play a key
More informationThe incidence of cardiovascular disease (CVD)
Review Paper Pathogenesis and Treatment of Microalbuminuria in Patients With Diabetes: The Road Ahead Rigas Kalaitzidis, MD; George Bakris, MD The incidence of type 2 diabetes is increasing in the United
More information( Diabetic nephropathy) ( Microalbuminuria ) ( Macroalbuminuria )
2006 17 99-105 2006 20-40% ( ESRD ) 30 299 mg ( ) ( 300 mgday ) DCCBs ) dihydropyridine calcium channel blockers ( non- DCCBs ( -blockers ( diuretics ) 10%) 0.8 ( 60 mlmin per 1.73 m 2 30 mlmin per 1.73
More informationHow To Treat Diabetes Mellitus
Diabetic nephropathy: Do all patients with Diabetes Mellitus benefit from an ACE-I or ARB? Carrie Rogers, Pharm.D. PGY2 Ambulatory Care Pharmacy Resident South Texas Veterans Health Care System The University
More informationHIGH BLOOD PRESSURE AND YOUR KIDNEYS
HIGH BLOOD PRESSURE AND YOUR KIDNEYS www.kidney.org About the Information in this Booklet Did you know that the National Kidney (NKF) Foundation offers guidelines and commentaries that help your healthcare
More informationUpdate in Contrast Induced Nephropathy
Update in Contrast Induced Nephropathy Yves Pirson Service de Néphrologie, Clin. Univ. St-Luc - UCL A 76-year-old man with - type 2 diabetes - CKD (ser. creat.: 1.8 mg/dl; GFR: 32) presents with angina
More information2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk Lynne T Braun, PhD, CNP, FAHA, FAAN Professor of Nursing, Nurse Practitioner Rush University Medical Center 2
More informationPosition Statement Diabetic Nephropathy American Diabetes Association
Information obtained from the American Diabetes Association 2002 by the American Diabetes Association, Inc. Publication Date January 2002 in Diabetes Care 25:S85-S89, 2002 Edited by the Nephrology Department,
More informationHow High Should an ACE Inhibitor or Angiotensin Receptor Blocker Be Dosed in Patients with Diabetic Nephropathy?
How High Should an ACE Inhibitor or Angiotensin Receptor Blocker Be Dosed in Patients with Diabetic Nephropathy? Marc S. Weinberg, MD, Nicholas Kaperonis, MD, and George L. Bakris, MD* Address *Hypertension
More informationDavid Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010
David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010 Objectives At the end of the talk, the participants will be able to: 1. Identify the increasing prevalence of type 2 diabetes
More informationManaging diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)
Managing diabetes in the post-guideline world Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Overview Pathogenesis of T2DM Aims of treatment The place of glycaemic control Strategies to improve glycaemic
More informationSupplementary Online Content
Supplementary Online Content James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report by the panel appointed to the Eighth Joint National
More informationHow To Know If Low Protein Diet Is Beneficial For Kidney Health
Protein Intake and Diabetic Kidney Disease Robert C. Stanton Joslin Diabetes Center 1/Serum Creatinine Plot Low Protein Protects in Renal Ablation Model 24% Protein Diet 6% Protein Diet Right Nephrectomy
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More informationCase Presentation: Mr. E.M. Dr. Braun
Case Presentation: Mr. E.M. Dr. Braun Case Presentation: Mr. E.M. 66 years old; PMHx CAD with stent 2010; carotid artery disease with stent 1999; aortic stenosis; CVA 1998; type 2 DM; colon cancer with
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationUCSF Kidney Transplant Symposium 2012
UCSF Kidney Transplant Symposium 2012 Nutrition Fitness in Kidney Transplant Mary Ellen DiPaola, RD, CDE UCSF Outpatient Dietitian Goal of Nutrition Fitness for Transplant Nutritional guidance of pre-
More informationPrevalence and risk factor of chronic kidney disease in elderly diabetic patients in Korea 성애병원 내과 김정한
Prevalence and risk factor of chronic kidney disease in elderly diabetic patients in Korea 성애병원 내과 김정한 Introduction CKD의 정의와 egfr의 측정 CKD의 risk factor와 mechanism 한국의 CKD prevalence 와 prognosis CKD의 치료와
More informationChronic Kidney Disease and Diabetes
Anyone with diabetes can get kidney disease. Diabetes and high blood pressure are the most common causes of kidney disease, and people often have both. Chronic (long term) kidney disease (CKD) caused by
More informationHigh Blood pressure and chronic kidney disease
High Blood pressure and chronic kidney disease For People with CKD Stages 1 4 www.kidney.org National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Did you know that the National Kidney
More information10/27/2010. CKD in the United States. Management of The Patient With Chronic Kidney Disease. CKD Patients Are More Likely to Die Than Progress to ESRD
CKD in the United States Management of The Patient With Chronic Kidney Disease Paul J. Scheel, Jr., M.D., FASN Director,Division of Nephrology An estimated 26 million adults have CKD Many are unaware of
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationRisk factors associated with the development of overt nephropathy in type 2 diabetes patients: A 12 years observational study
Indian J Med Res 136, July 2012, pp 46-53 Risk factors associated with the development of overt nephropathy in type 2 diabetes patients: A 12 years observational study Vijay Viswanathan, Priyanka Tilak
More informationApproaches to the Management of Difficult-to-Control Hypertension
Approaches to the Management of Difficult-to-Control Theodore D Fraker, Jr, MD Professor of Medicine The Ohio State University Medical Center Orlando, Florida October 7-9, 2011 Case Study: DM 64 year old
More informationAbsolute cardiovascular disease risk management
Quick reference guide for health professionals Absolute cardiovascular disease risk management This quick reference guide is for use by health professionals for primary prevention of cardiovascular disease
More informationMANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING
More informationEvidence-Based Secondary Stroke Prevention and Adherence to Guidelines
Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines Mitchell S.V. Elkind, MD, MS Associate Professor of Neurology Columbia University New York, NY Presenter Disclosure Information Mitchell
More informationOUTPATIENT MANAGEMENT OF CHRONIC KIDNEY DISEASE. Jeanie Park, MD MS Assistant Professor Renal Division Emory University School of Medicine
OUTPATIENT MANAGEMENT OF CHRONIC KIDNEY DISEASE Jeanie Park, MD MS Assistant Professor Renal Division Emory University School of Medicine Disclosures None Goals Background and staging Strategies to slow
More informationHigh Blood Pressure and Your Kidneys
High Blood Pressure and Your Kidneys About 65 million Americans have high blood pressure, but as many as one third or three in 10 don't even know it. There are usually no signs or symptoms that your blood
More informationInDependent Diabetes Trust
InDependent Diabetes Trust Kidneys and Diabetes Updated July 2015 Registered Company Number 3148360 Registered Charity No 1058284 Contents Introduction Healthy Kidneys Kidney disease and diabetes The use
More informationEpidemiology of Hypertension 陈 奕 希 3120000591 李 禾 园 3120000050 王 卓 3120000613
Epidemiology of Hypertension 陈 奕 希 3120000591 李 禾 园 3120000050 王 卓 3120000613 1 Definition Hypertension is a chronic medical condition in which the blood pressure in the arteries is elevated. 2 Primary
More informationQuick Reference Guide
2013 Clinical Practice Guidelines Quick Reference Guide (Updated March 2016) 416569-16 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Copyright 2016 Canadian Diabetes Association SCREENING
More informationStroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012
Faculty Prevention Sharon Ewer, RN, BSN, CNRN Stroke Program Coordinator Baptist Health Montgomery, Alabama Satellite Conference and Live Webcast Monday, May 21, 2012 2:00 4:00 p.m. Central Time Produced
More informationModels of Chronic Kidney Disease Care and Initiation of Dialysis. Dr Paul Stevens Kent Kidney Care Centre East Kent Hospitals, UK
Models of Chronic Kidney Disease Care and Initiation of Dialysis Dr Paul Stevens Kent Kidney Care Centre East Kent Hospitals, UK Early Crash Landings Talk Outline Pathways & Definitions Guideline recommendations
More informationCase study 28: Managing hypertension in diabetes
Case study 28: Managing hypertension in diabetes October 2003 An Independent, Australian organisation for Quality Use of Medicines National Prescribing Service Limited ACN 082 034 393 Level 7/418A Elizabeth
More informationThe Canadian Diabetes Association s 2013 Clinical Practice Guidelines and the Pharmacist Rob Roscoe, B.Sc.Pharm., ACPR, CDE, CPT
Welcome! Thank you for joining the webinar: The Canadian Diabetes Association s 2013 Clinical Practice Guidelines and the Pharmacist Rob Roscoe, B.Sc.Pharm., ACPR, CDE, CPT The webinar will begin shortly.
More informationIsabella Sudano & Franco Muggli
Swiss Hypertension Guidelines Isabella Sudano & Franco Muggli CoLaus, Swisshype ESC 2005 Dokumentenname Datum Seite 1 European Journal of Cardiovascular Prevention and Rehabilitation 2009 Guideline...
More informationCorrespondence to: Rima B Shah (rima_1223@yahoo.co.in) DOI: 10.5455/ijmsph.2013.2.167-172 Received Date: 29.11.2012 Accepted Date: 03.12.
RESEARCH ARTICLE STUDY OF UTILIZATION PATTERN OF ANTI-HYPERTENSIVE DRUGS IN HYPERTENSIVE DIABETIC PATIENTS WITH OR WITHOUT REDUCED RENAL FUNCTION AT TERTIARY CARE TEACHING HOSPITAL Jay Shah 1, Tejas Khakhkhar
More informationCardiovascular Disease in Diabetes
Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality
More informationHigh Blood Pressure (Essential Hypertension)
Sacramento Heart & Vascular Medical Associates February 18, 2012 500 University Ave. Sacramento, CA 95825 Page 1 916-830-2000 Fax: 916-830-2001 What is essential hypertension? Blood pressure is the force
More informationGetting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot
Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:
More informationWorld Kidney Day 11 March 2010: we must act on diabetic kidney disease
November 11, 2009 Diabetic kidney disease: Act now or pay later Robert C Atkins and Paul Zimmet For the 2010 International Society of Nephrology/International Federation of Kidney Foundations World Kidney
More informationTreating Hypertension in the Patient With Overt Diabetic Nephropathy. Edmund J. Lewis, MD
Treating Hypertension in the Patient With Overt Diabetic Nephropathy Edmund J. Lewis, MD Summary: Arterial blood pressure is a major determinant of renal and cardiovascular outcomes in diabetic nephropathy.
More informationPrimary prevention of chronic kidney disease: managing diabetes mellitus to reduce the risk of progression to CKD
Primary prevention of chronic kidney disease: managing diabetes mellitus to reduce the risk of progression to CKD Date written: July 2012 Author: Kate Wiggins, Graeme Turner, David Johnson GUIDELINES We
More informationPrescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital
Research Article Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital *T. JANAGAN 1, R. KAVITHA 1, S. A. SRIDEVI
More informationHow To Determine The Prevalence Of Microalbuminuria
Research Journal of Pharmaceutical, Biological and Chemical Sciences Prevalence of Microalbuminuria in relation to HbA1c among known Type2 Diabetic Patients in Puducherry population Muraliswaran P 1 *,
More informationHypertension in Chronic Kidney Disease Vito M. Campese, MD
Hypertension in Chronic Kidney Disease Vito M. Campese, MD Professor of Medicine, Physiology and Biophysics Division of Nephrology and Hypertension Center Co-Director USC/UKRO Kidney Research Center Keck
More informationBoard Review: Hypertension Cases
Board Review: Hypertension Cases Cheryl L. Laffer, MD, PhD, FAHA Associate Professor of Medicine, Texas A&M HSC College of Medicine Senior Staff, S&W Nephrology / Hypertension (Remember, I didn t make
More informationAbsolute cardiovascular disease risk assessment
Quick reference guide for health professionals Absolute cardiovascular disease risk assessment This quick reference guide is a summary of the key steps involved in assessing absolute cardiovascular risk
More informationIdentifying and treating long-term kidney problems (chronic kidney disease)
Understanding NICE guidance Information for people who use NHS services Identifying and treating long-term kidney problems (chronic kidney disease) NICE clinical guidelines advise the NHS on caring for
More informationThe Hypertension Treatment Center
Patricia F. Kao MD MS Asst Professor, EVMS Nephrology & HTN April 26, 2014 The Hypertension Treatment Center I have no conflicts of interest to disclose Objectives Describe the role of Hypertension Treatment
More information